课题基金 / 基金详情

Protein Glycation and the Proteasome: Role in Neurological Diseases and Aging

Protein Glycation and the Proteasome: Role in Neurological Diseases and Aging
蛋白质糖化和蛋白酶体:在神经系统疾病和衰老中的作用
批准号:
8699645
负责人:
Pamela Anne Maher
金额:
$24.25万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-07-15 至 2016-06-30

项目摘要

项目成果

Pamela Anne Maher的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):与其他器官相似,大脑功能随着年龄的增长而下降。事实上,认知和运动功能的下降是正常衰老的特征之一,导致学习和记忆的变化以及平衡和协调的缺陷。年龄也是包括阿尔茨海默病(AD)在内的各种神经系统疾病的最大风险因素。由于许多西方国家的平均年龄正在增加,确定减少衰老对大脑功能影响的方法正在进行 新的紧迫性。已经提出的导致大脑功能随年龄下降的因素之一是蛋白质加工的改变。这是如何以及为什么发生的尚不清楚,但我们假设它与甲基乙二醛(MG)的增加密切相关,因此,蛋白质糖化。糖与蛋白质的非酶促加成导致晚期糖基化终产物(AGEs)的形成。虽然糖化蛋白的形成增强最初与糖尿病有关,但现在认识到这种蛋白质修饰在正常衰老期间也会增加,并且在年龄依赖性神经退行性疾病如阿尔茨海默病(AD)中会加剧。MG是负责AGE形成的主要反应性醛之一。它是糖酵解的副产物,但也可以直接或间接从饮食来源获得。已经提出多种因素有助于衰老过程,包括氧化还原稳态、蛋白质加工、线粒体功能和免疫应答的改变。虽然这些变化似乎是相当不同的,它是假设,他们是由一个共同的因素,MG。为了支持这一观点,糖酵解速率的降低已被证明可以增加寿命,而蛋白质加工尤其是蛋白酶体功能的损伤对培养细胞和动物模型中的衰老都有负面影响。最近的证据表明,MG可以直接和间接抑制蛋白酶体活性,通过特定的蛋白酶体亚基的修饰。此外,MG和泛素都共价修饰赖氨酸残基上的蛋白质。由于泛素依赖的途径是去除许多聚集的、错误折叠的或氧化的蛋白质所必需的,因此蛋白质的糖化可能会阻碍泛素 依赖性降解因此,进一步假设MG-蛋白糖基化的年龄依赖性增加和蛋白酶体功能的年龄依赖性降低直接相关并导致认知功能障碍。拟议的研究旨在使用细胞培养研究和AD动物模型来验证这一假设。
英文摘要
DESCRIPTION (provided by applicant): Similar to other organs, brain function declines with age. Indeed, a decline in both cognitive and motor functions is one of the characteristics of normal aging, resulting in changes in learning and memory as well as deficits in balance and coordination. Age is also the single greatest risk factor for a variety of neurological disorders including Alzheimer's disease (AD). Since the average age in many Western countries is increasing, identifying approaches for reducing the effects of aging on brain function is taking on a new urgency. Among the factors that have been proposed to contribute to the decrease in brain function with age are alterations in protein processing. How and why this occurs is unclear but we hypothesize that it is tightly linked to increases in methylglyoxal (MG) and, in consequence, protein glycation. The non-enzymatic addition of sugars to proteins results in the formation of advanced glycation end- products (AGEs). Although the enhanced formation of glycated proteins was initially associated with diabetes, it is now recognized that this protein modification is also increased during normal aging and is exacerbated in age-dependent neurodegenerative diseases such as Alzheimer's disease (AD). MG is one of the major reactive aldehydes responsible for AGE formation. It is a by-product of glycolysis but can also be obtained both directly and indirectly from dietary sources. Multiple factors have been proposed to contribute to the aging process including alterations in redox homeostasis, protein processing, mitochondrial function and the immune response. Although these alterations appear to be quite diverse, it is hypothesized that they are linked by a common factor, MG. In support of this idea, a reduction in the glycolytic rate has been shown to increase longevity while impairments in protein processing and especially proteasome function have negative effects on aging both in cultured cells and in animal models. Recent evidence suggests that MG can both directly and indirectly inhibit proteasome activity via modification of specific proteasome subunits. Furthermore, both MG and ubiquitin covalently modify proteins on lysine residues. Since ubiquitin-dependent pathways are required for the removal of many aggregated, misfolded, or oxidized proteins, it is possible that the glycation of proteins can hinder ubiquitin dependent degradation. Thus, it is further hypothesized that age-dependent increases in MG-protein glycation and age-dependent decreases in proteasome function are directly linked and contribute to cognitive dysfunction. The proposed research is designed to test this hypothesis using both cell culture studies and an animal model of AD.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.freeradbiomed.2017.03.028
发表时间: 2017-07
期刊: Free radical biology & medicine
影响因子: 7.4
作者: [Dafre AL, Schmitz AE, Maher P]
通讯作者: Maher P
Phase 1 Clinical Trial of CMS121, a Novel Therapeutic Candidate for Alzheimer's Disease
  • 批准号:
    10307970
  • 项目类别:
  • 资助金额:
    $250.32万
  • 财政年份:
    2021
  • 负责人:
    Pamela Anne Maher
  • 依托单位:
Phase 1 Clinical Trial of CMS121, a Novel Therapeutic Candidate for Alzheimer's Disease
  • 批准号:
    10553057
  • 项目类别:
  • 资助金额:
    $25.17万
  • 财政年份:
    2021
  • 负责人:
    Pamela Anne Maher
  • 依托单位:
Phase 1 Clinical Trial of CMS121, a Novel Therapeutic Candidate for Alzheimer's Disease
  • 批准号:
    10542565
  • 项目类别:
  • 资助金额:
    $21.01万
  • 财政年份:
    2021
  • 负责人:
    Pamela Anne Maher
  • 依托单位:
Using geroscience to understand and treat Alzheimer's disease
海外基金